Latest Oncolytic virus Stories
Medulloblastoma is the most common malignant brain tumor in children. Disseminated medulloblastoma is particularly lethal and requires extensive radiation therapy to the brain, which can cause brain damage. An oncolytic measles virus has shown effectiveness in a new model of disseminated human medulloblastoma. A strain of measles virus engineered to kill cancer cells prolongs survival in a model of medulloblastoma that is disseminated in the fluid around the brain,...
SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that Gregory Schafer, the company's chief financial officer, is scheduled to present at the 14th Annual BIO CEO & Investor Conference next week in New York City. The presentation is scheduled for Monday, February 13, 2012, at 4:30 p.m. ET. This...
SAN FRANCISCO, Feb. 7, 2012 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced the publication in Molecular Therapy of data validating the mechanisms by which its lead product, JX-594, selectively targets and kills a broad range of cancer cells. The study demonstrated that JX-594's cancer-selectivity was multi-mechanistic...
Cancer is one of the most common causes of death in humans. The conventional cancer therapies include surgery, radiotherapy, chemotherapy, and targeting therapies, which are intended to directly destroy and eliminate tumor cells. These treatments often fail, resulting in tumor metastasis and recurrence. Therefore, there is a critical need for novel cancer therapies. In recent years, an increasing number of studies have revealed that immune responses play a critical role in conventional cancer...
SAN FRANCISCO, Dec. 21, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 2a clinical trial of JX-594 as a neoadjuvant therapy in patients who are undergoing surgery to treat colorectal cancer that has spread to the liver. The study is being led by Rebecca Auer,...
Adenoviruses can cause respiratory, eye, and intestinal tract infections, and, like other viruses, must hijack the cellular machinery of infected organisms in order to produce proteins and their own viral spawn. Now an international research team made up of scientists from Chinese and Australian universities has found a way to disrupt the hijacking process by using plasma to damage the viruses in the laboratory environment, before they come into contact with host cells. The researchers...
Recruitment is ongoing at Texas Children's Cancer Center for a Phase 1 clinical trial in children with cancer using a novel immunotherapy approach called oncolytic virus therapy. The trial, launched last spring and led by Dr. Chrystal Louis, assistant professor of pediatric hematology/oncology at Baylor College of Medicine, is also being conducted at Cincinnati Children's Hospital. Immune cells destroy cancer cells “This approach uses a modified smallpox virus that kills tumor...
SAN FRANCISCO, Nov. 5, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class targeted oncolytic products for cancer, today presented final data from a randomized dose-ranging Phase 2 clinical trial of JX-594 in patients with advanced liver cancer showing a statistically significant benefit in overall survival for the high JX-594 dose group versus the low dose group. The final data...
SAN FRANCISCO, Nov. 4, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE. The trial is evaluating the use of JX-594 to treat patients with advanced...
SAN FRANCISCO, Nov. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that final data from its Phase 2 randomized clinical trial in advanced liver cancer patients will be presented on Monday, November 7, 2011 at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 4-8,...
